PRME
HealthcarePrime Medicine, Inc.
$3.57
+$0.04 (+1.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Prime Medicine, Inc. is a biotechnology company in the healthcare sector with a significant market presence. The company has a market capitalization of $644.42 million, indicating its substantial scale. With revenue totaling $5.98 million and 214 employees, Prime Medicine has a relatively small but focused workforce. From a financial perspective, Prime Medicine's profitability metrics are concerning. The company reported a net income loss of $197.34 million in the trailing twelve months (TTM), with an operating margin of -4406.0% and profit margin of 0.0%. This is reflected in its negative return on equity (-112.3%) and return on assets (-35.5%). The company's balance sheet shows a significant debt-to-equity ratio of 73.00, but it also has substantial cash reserves of $213.29 million. In terms of valuation context, Prime Medicine's forward P/E ratio is -3.96, indicating a current market expectation of negative earnings growth in the near term. The company's revenue growth rate was 486.1% year-over-year (YoY), but this metric is not available for earnings growth. Prime Medicine does not pay dividends, as its payout ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $644.42M
- P/E Ratio
- N/A
- 52-Week High
- $6.94
- 52-Week Low
- $1.11
- Avg Volume
- 3.96M
- Beta
- 2.72
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 214